(Updates)
** U.S.-listed shares of Israel-based therapy developer Compugen fall ~3% to $1.62 premarket
** Switzerland-based Roche's drug tiragolumab, which is part of a new class of drugs known as anti-TIGIT, failed a lung cancer treatment trial on Thursday
** CGEN has colorectal, ovarian and lung cancer treatments in development that work by acting on the TIGIT receptor, which suppresses the proliferation and activation of cells of the immune system
** Other anti-TIGIT drugmakers Iteos Therapeutics down 8.6% and Arcus Biosciences down 3.5%
** Up to last close, CGEN down 15.6%, RCUS down 24.8% and ITOS up 35% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Comments